BRSK2

Across TCGA pan-cancer cohorts, BRSK2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BRSK2 data layer compared with 29 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BRSK2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BRSK2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC and GBM are the cancer types where BRSK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.245	0.934	.038	3	view →
GBM	DFS	Quartile	All	0.839	0.649	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

BRSK2–PDAC (DFS)

Open the PDAC breakdown →